When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits.

New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on joints that hurt with osteoarthritis. They can reduce inflammation that does much of the damage.

A Metabolic Benefit

When NEJM published an RCT demonstrating a benefit for semaglutide in osteoarthritis, an editorial pointed to this possibility. Now, a new study in Cell Metabolism provides evidence to support that speculation. Hongyu Qin and colleagues conducted animal and human studies to document a metabolic pathway for semaglutide to reduce inflammation from osteoarthritis. They conclude that better regulation of energy metabolism is key – because it may be the reason for the benefit of semaglutide and similar drugs in osteoarthritis and obesity:

“Intricate regulation of energy metabolism, ensuring neither excessive nor insufficient ATP production, is essential for sustaining health and longevity. GLP-1R agonists, by fine-tuning energy metabolism, may exert systemwide benefits beyond glucose regulation. This metabolic precision could explain their promising effects in diverse diseases, including osteoarthritis.”

It’s Not Just the Weight

Once again, we see that obesity is about more than just excess weight. If we focus on weight loss and lose sight of metabolic dysfunction, we risk missing out on understanding the full benefits of treating obesity.

Click here for the study in Cell Metabolism, here and here for more about semaglutide in osteoarthritis and obesity.

Osteoarthritis of the Left Knee, photograph by James Heilman, MD, licensed under CC BY-SA 3.0